# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elizabeth Barrett Browning (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI026-SYN
- Date: 2026-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clementine Haverford-Asante, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week review: cultures, airway clearance, bone density, grief therapy, and the opioid dose. **S**

## History of present illness

Ms. Barrett Browning returns four weeks after the consultation. She does airway clearance every morning and evening and finds it tiring but worth it: her sputum is down from about four to two tablespoons a day, and she has seen no blood for two weeks. She has had four grief therapy sessions by video and says it is the first time she has spoken of her brother aloud; the first two sessions were very hard. She sleeps a little better. She had her DXA scan last week. She asks whether she could try a lower morphine dose, now that the cough is easing and she is sleeping a little better, but she does not want to stop it and is afraid of the restlessness she remembers when a dose was late. **S**

| Element | Detail |
|---|---|
| Airway clearance | Twice daily; sputum down to two tablespoons a day; no blood for two weeks |
| Mycobacterial cultures | No growth at four weeks |
| Grief therapy | Four sessions |
| Her request | A slow, small reduction in morphine |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; a little more energy |
| Respiratory | Positive | Cough with two tablespoons of sputum a day; no blood |
| Gastrointestinal | Positive | Stools every two days; no pain |
| Psychiatric | Positive | Grief still heavy but more bearable; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 **S**
- Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth daily **S**
- Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day) **S**

## Allergies

- No known allergy **S**

## Objective

BP 104/66 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 42.4 kg; BMI 17.2 kg/m². All vital signs are synthetic.

Lumbar spine Z-score: -1.4; Femoral neck Z-score: -1.1; C-reactive protein: 4.1 mg/L; PHQ-9: 10. All results are synthetic.

## Change since baseline

- C-reactive protein: 8.4 mg/L (high) at baseline, 4.1 mg/L at this visit **S**
- PHQ-9: 12 at baseline, 10 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Brighter; weight 42.4 kg |
| Respiratory | Fewer crackles at the left base; no wheeze |
| Neurological | Not drowsy; pupils normal size |
| Psychiatric | Engaged; tearful briefly when speaking of her brother; no suicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bronchiectasis** (J47.9). Responding to airway clearance: less sputum, no blood, CRP 4.1 mg/L. Mycobacterial cultures show no growth at four weeks. The sputum culture sent last week again grew a light growth of Haemophilus influenzae. **S**
   - Continue airway clearance twice daily.
   - Final cultures at the next visit.
2. **Long-term opioid therapy: her request to reduce** (Z79.891). No opioid use disorder; she wants a slow reduction because the cough and sleep are improving and she would rather not damp the cough. A reduction of about 10 percent with each step held at least four weeks is reasonable; she can pause or go back a step at any time, and nothing will be forced. **S**
   - Morphine solution 4.5 mL (9 mg) twice daily from today.
   - Call if restlessness, sweating or sleeplessness lasts more than a few days.
   - Prescription monitoring program checked: one prescriber, one pharmacy.
3. **Prolonged grief disorder** (F43.81). PHQ-9 10 from 12 after four sessions; no suicidal ideation. **S**
   - Continue weekly grief therapy.
   - Safety plan reviewed.
4. **Vitamin D deficiency and bone health** (E55.9). DXA Z-scores -1.4 at the spine and -1.1 at the femoral neck: within the expected range for age, at the low end, as expected with her low weight and indoor life. No drug treatment needed. **S**
   - Continue vitamin D3 2000 units daily; recheck at twelve weeks.
   - Weight-bearing exercise in the home program.
   - Calcium from food, about 1000 mg a day.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Mycobacterial culture including nontuberculous mycobacteria | At diagnosis (final at six to eight weeks), then yearly and with unexplained decline | Ordered | No growth at four weeks; final at eight weeks |
| Laboratory | Sputum bacterial culture | At each review and at every exacerbation, before antibiotics | Completed today | Light growth of Haemophilus influenzae; no Pseudomonas |
| Laboratory | C-reactive protein | With symptoms or exacerbation | Completed today | 4.1 mg/L, from 8.4 |
| Self-management | Airway clearance technique and exercise | Every visit | Completed today | Twice daily with the oscillating PEP device; technique checked by the physiotherapist last week |
| Self-management | Exacerbations: number in the past year, written plan, and rescue antibiotic | Every visit | Completed today | None since diagnosis; plan and antibiotic at home |
| Self-management | Hemoptysis: amount, and when to seek emergency care | Every visit | Completed today | No blood for two weeks |
| Medication safety | Opioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goals | Every visit, and at least every three months | Completed today | No sedation; cough and sleep improving; she chose a reduction |
| Medication safety | Prescription drug monitoring program check | With every prescription, and at least every three months | Completed today | One prescriber, one pharmacy |
| Medication safety | Naloxone at home, and no benzodiazepines or other sedatives | Every visit | Completed today | Naloxone at home; no sedatives |
| Medication safety | Opioid use disorder assessment (DSM-5-TR) | At review and whenever there is concern; tolerance and withdrawal on prescribed use do not count | Completed today | No criteria met apart from tolerance and withdrawal, which do not count on prescribed use |
| Survey | PHQ-9 | At least monthly during active treatment (CMID) | Completed today | 10, from 12 |
| Examination | Suicide risk review and safety plan | Every visit | Completed today | No suicidal ideation; plan current |
| Self-management | Grief therapy attendance and response | Weekly for sixteen sessions | Completed today | Four sessions attended |
| Imaging | Bone density (DXA) | Once, for risk factors; repeat only if risk changes | Completed today | Spine Z -1.4, femoral neck Z -1.1: within the expected range |
| Laboratory | 25-hydroxyvitamin D | Twelve weeks after starting replacement, then yearly; target 30 ng/mL or more (CMID) | Due | 15 ng/mL at intake; recheck at twelve weeks |
| Examination | Weight and BMI | Every visit | Completed today | 42.4 kg, BMI 17.2, up 0.9 kg |

## Goal progress

- Tuberculosis excluded and a diagnosis for the cough within two weeks. Outcome by 2026-03-23: Smears, NAAT and IGRA negative within a week; bronchiectasis diagnosed by CT at one week. **S**
- Airway clearance twice daily, with less sputum and no blood in it, by three months. In progress; target 2026-06-15. **S**
- Safe opioid therapy: naloxone at home, no overdose or sedation, and any dose change only by her choice. In progress; target 2026-10-19. **S**
- Response of grief and depressive symptoms (PHQ-9 down by at least half) by six months. In progress; target 2026-10-19. **S**
- Weight up toward a BMI of 18.5 (45.6 kg) by seven months. In progress; target 2026-10-19. **S**
- Vitamin D above 30 ng/mL by twelve weeks. In progress; target 2026-06-15. **S**

## Medication changes

- Started: Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day) **S**

## Guideline basis

- British Thoracic Society Guideline for Bronchiectasis in Adults (2019), British Thoracic Society (Thorax 2019;74 Suppl 1:1-69)
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017), ATS, IDSA and CDC (Clin Infect Dis 2017;64(2):111-115)
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020), ATS, ERS, ESCMID and IDSA (Clin Infect Dis 2020;71(4):e1-e36)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR): opioid use disorder and prolonged grief disorder criteria (2022), American Psychiatric Association
- Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016), JAMA Psychiatry 2016;73(7):685-694
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026), Aether Forge

## Follow-up

- Three-month review with the final mycobacterial cultures, vitamin D, PHQ-9 and GAD-7, and a check on the first dose step. Emergency care for more than a few teaspoons of blood. **S**
- Next scheduled visit 2026-06-15: three-month review: final mycobacterial cultures, vitamin D, mood, safety, and the opioid dose. **S**
